Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL5925 Target Snapshot

Ectonucleotide pyrophosphatase/phosphodiesterase family member 1 · SINGLE PROTEIN · Homo sapiens

646Compounds
154Assays
0Approved Drugs
747.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Protein identity stays anchored to UniProt P22413. Use UniProt P22413 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt P22413 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Ectonucleotide pyrophosphatase/phosphodiesterase family member 1 as ChEMBL target CHEMBL5925, mapped to UniProt P22413. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Ectonucleotide pyrophosphatase/phosphodiesterase family member 1
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL5925
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
P22413
Ectonucleotide pyrophosphatase/phosphodiesterase family member 1
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Ectonucleotide pyrophosphatase/phosphodiesterase family member 1 is the right protein anchor across sources, using UniProt P22413 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelEctonucleotide pyrophosphatase/phosphodiesterase family member 1
UniProt AccessionP22413
Component TypeProtein
Sequence Length925 aa

Ectonucleotide pyrophosphatase/phosphodiesterase family member 1

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Ectonucleotide pyrophosphatase/phosphodiesterase family member 1, mapped to UniProt P22413. Sequence length is 925 aa.

Mapped IDP22413
Review nameEctonucleotide pyrophosphatase/phosphodiesterase family member 1
OrganismHomo sapiens
Clinical Profile

Clinical Phase Distribution

2
Phase III
Assay Mix

Activity Type Distribution

IC50524.0
KI223.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL5566114 10.05 IC50 0.09 Preclinical
CHEMBL5556000 9.8 IC50 0.16 Preclinical
CHEMBL5826130 9.66 IC50 0.22 Preclinical
CHEMBL5560511 9.52 IC50 0.3 Preclinical
CHEMBL5561670 9.32 IC50 0.48 Preclinical
CHEMBL5915707 9.3 IC50 0.5 Preclinical
CHEMBL5555976 9.28 IC50 0.52 Preclinical
CHEMBL5566818 9.25 IC50 0.56 Preclinical
CHEMBL5558246 9.18 IC50 0.66 Preclinical
CHEMBL5558533 9.14 IC50 0.72 Preclinical
Distribution

pChEMBL Value Distribution

103
5.0
90
5.5
79
6.0
87
6.5
56
7.0
28
7.5
24
8.0
9
8.5
10
9.0
3
9.5
pChEMBL
Assay Landscape

Assay Landscape

154
Total Assays
411
Tested Compounds
2
Assay Types
Binding — 141 assays, 411 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 67 132 6.2
single protein format 66 229 6.3
assay format 4 42 5.7
cell membrane format 4 8 5.6
ADME — 13 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 11 0
cell-based format 2 0

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine